Sitagliptin Tablet, Film Coated
Product Images NDC 60505-3645

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sitagliptin (NDC 60505-3645). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apotex Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Btl-lbl-100mg-30s (Btl Lbl 100mg 30s)

Each film-coated tablet contains 128.5 mg of sitagliptin phosphate, equivalent to 100 mg sitagliptin. These tablets should be stored at 20°C to 25°C (68°F to 77°F) with excursions permitted from 15°C to 30°C (59°F to 86°F). The medication should be dispensed in a tight container and the usual dosage information can be found in the package insert. The tablets are manufactured for Apotex Corp. and come in a container of 30 tablets. Pharmacists are advised to dispense with a Medication Guide available at the provided website for each patient.*

FDA Label Image

Btl-lbl-100mg-90s (Btl Lbl 100mg 90s)

This is a description for Sitagliptin phosphate tablets containing 100 mg of sitagliptin. The tablets are film-coated and should be stored at a temperature range between 20°C to 25°C. The usual dosage information is available in the package insert. The tablets are dispensed in a tight container and are manufactured by Agotex Inc for Sitagliptin SEL Tablets, USP 100 mg. Pharmacies should dispense these tablets with a medication guide available online for patients.*

FDA Label Image

Btl-lbl-25mg-30s (Btl Lbl 25mg 30s)

Each film-coated tablet of Sitagliptin contains 32.13 mg of sitagliptin phosphate, equivalent to 25 mg sitagliptin. Store between 20°C to 25°C (68°F to 77°F) with excursions allowed from 15°C to 30°C (59°F to 86°F). These tablets are manufactured by Apotex Inc in Toronto, Ontario, Canada, and distributed by Apotex Corp in Weston, Florida. The packaging includes 30 tablets with the NDC code 60505-3643-3. To know more about the product, refer to the package insert and dispense in a tight container. This medication is available for sale through Apotex Corp only.*

FDA Label Image

Btl-lbl-25mg-90s (Btl Lbl 25mg 90s)

Each film-coated tablet contains 32.13 mg of sitagliptin phosphate, equivalent to 25 mg sitagliptin. The tablets should be stored at 20°C to 25°C (68°F to 77°F), with excursions permitted from 15°C to 30°C (59°F to 86°F). The product should be dispensed in a tight container as per USP guidelines. The usual dosage information can be found in the package insert. This medication is manufactured by Apotex Inc. in Canada, and is intended for dispensing by pharmacists with a Medication Guide available for patients.*

FDA Label Image

Btl-lbl-50mg-30s (Btl Lbl 50mg 30s)

This is a description of a medication containing 64.25 mg of sitagliptin phosphate per film-coated tablet, with each bottle containing 30 tablets equivalent to 50 mg of sitagliptin. The medication is manufactured by Apotex Corp. and should be stored at a temperature range of 20°C to 25°C. The usual dosage is 50 mg, and it should be dispensed in a tight container with the package insert. Pharmacists are instructed to provide a Medication Guide available at the provided website to each patient.*

FDA Label Image

Btl-lbl-50mg-90s (Btl Lbl 50mg 90s)

This text provides details about a medication in tablet form, containing 64.25 mg of sitagliptin phosphate, equivalent to 50 mg of sitagliptin. The tablets are film-coated and come in a bottle of 90 tablets. The manufacturer is Apotex Corp, based in Weston, Florida. Storage instructions recommend storing the tablets at 20°C to 25°C, with excursions permitted from 15°C to 30°C. The usual dosage is 50 mg, and the package insert should be consulted for more information. The medication should be dispensed in a tight container, and pharmacists are advised to dispense with the Medication Guide available at the provided website.*

FDA Label Image

Figure1 (Figure1)

This text contains information related to the LS Mean Change from Baseline over different weeks for various treatment groups including Placebo, Metformin, Sitagliptin, and combinations of Metformin and Sitagliptin of different doses. The data seems to represent a clinical study or trial evaluating the efficacy of different treatments over time.*

FDA Label Image

Figure2 (Figure2)

This text appears to be a table that shows the LS Mean Change from Baseline for a comparison between two medications, "Sitagliptin 100 mg" and "Gipizide." The data seems to include measurements at different time points (03, 06, 09, etc.) and possibly at different dosages or conditions. The table also includes numerical values possibly representing changes in a specific parameter or outcome over time. Without further context, it is difficult to provide a more detailed analysis.*

FDA Label Image

Chemical-structure (Sitagliptin 01)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.